Terms: = Germ cell tumor AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
114 results:
1. Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.
Qin L; Zhang G; Wu Y; Yang Y; Zou Z
Cancer Immunol Immunother; 2024 Apr; 73(6):103. PubMed ID: 38630135
[TBL] [Abstract] [Full Text] [Related]
2. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract] [Full Text] [Related]
3. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
4. Metabolic imaging in recurrent gliomas: comparative performance of 18F-FDOPA, 18F-fluorocholine and 18F-FDG PET/CT.
Sharma A; Garg A; Singh M; Sharma MC; Gupta S; Kunhiparambath H; Tripathi M; Kale SS; Bal C
Nucl Med Commun; 2024 Feb; 45(2):139-147. PubMed ID: 38095139
[TBL] [Abstract] [Full Text] [Related]
5. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
[TBL] [Abstract] [Full Text] [Related]
6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract] [Full Text] [Related]
7. NLGN4X TCR transgenic T cells to treat gliomas.
Krämer C; Kilian M; Chih YC; Kourtesakis A; Hoffmann DC; Boschert T; Koopmann P; Sanghvi K; De Roia A; Jung S; Jähne K; Day B; Shultz LD; Ratliff M; Harbottle R; Green EW; Will R; Wick W; Platten M; Bunse L
Neuro Oncol; 2024 Feb; 26(2):266-278. PubMed ID: 37715782
[TBL] [Abstract] [Full Text] [Related]
8. tumor lysis syndrome induced by tebentafusp.
Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
[TBL] [Abstract] [Full Text] [Related]
9. Skin-Grafting and Dendritic cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines.
Zeng B; Moi D; Tolley L; Molotkov N; Frazer IH; Perry C; Dolcetti R; Mazzieri R; Cruz JLG
Cells; 2023 Aug; 12(16):. PubMed ID: 37626903
[TBL] [Abstract] [Full Text] [Related]
10. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.
Takei J; Kamata Y; Tanaka T; Fukasawa N; Gomisawa K; Satake M; Mori R; Yamamoto Y; Suzuki T; Oda A; Murahashi M; Fukuda T; Shimoda M; Murayama Y; Akasaki Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3175-3189. PubMed ID: 37382632
[TBL] [Abstract] [Full Text] [Related]
12. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303
[TBL] [Abstract] [Full Text] [Related]
13. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.
Frankiw L; Singh A; Peters C; Comin-Anduix B; Berent-Maoz B; Macabali M; Shammaie K; Quiros C; Kaplan-Lefko P; Baselga Carretero I; Ribas A; Nowicki TS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37156551
[TBL] [Abstract] [Full Text] [Related]
14. Evolving Management of Stage IV Melanoma.
Switzer B; Piperno-Neumann S; Lyon J; Buchbinder E; Puzanov I
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e397478. PubMed ID: 37141553
[TBL] [Abstract] [Full Text] [Related]
15. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract] [Full Text] [Related]
16. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
[TBL] [Abstract] [Full Text] [Related]
17. Tebentafusp in the treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Montazeri K; Pattanayak V; Sullivan RJ
Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
[TBL] [Abstract] [Full Text] [Related]
18. Definition and Characterization of SOX11-Derived T cell Epitopes towards Immunotherapy of Glioma.
Liu Y; Keib A; Neuber B; Wang L; Riemer AB; Bonsack M; Hückelhoven-Krauss A; Schmitt A; Müller-Tidow C; Schmitt M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768267
[TBL] [Abstract] [Full Text] [Related]
19. H3.3K27M mutation is not a suitable target for immunotherapy in hla-a2
Immisch L; Papafotiou G; Popp O; Mertins P; Blankenstein T; Willimsky G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302563
[TBL] [Abstract] [Full Text] [Related]
20. Tebentafusp for the treatment of hla-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN; Carvajal RD
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
[TBL] [Abstract] [Full Text] [Related]
[Next]
